An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

Trial Profile

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer; Gastrointestinal cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Thoracic neoplasms
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 1 Oct 2018 to 1 Sep 2018.
    • 05 Oct 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Mar 2018.
    • 22 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top